Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Verrica will webcast its September 14, 2026 H.C. Wainwright conference presentation and offer a replay for 90 days for investors.

Rhea-AI Summary

Verrica Pharmaceuticals (VRCA) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 1:00 p.m. ET in New York, NY.

President and CEO Jayson Rieger, PhD, MBA, is scheduled to speak. A live webcast will be available via a provided link and in the Investors/Presentations & Events section of Verrica’s website, with a replay accessible for 90 days after the event.

Verrica develops and commercializes treatments for dermatological diseases, including skin cancers. Its FDA-approved product YCANTH (VP-102) treats molluscum contagiosum in patients aged two years and older and is also being developed for common warts. Verrica also holds a worldwide license with Lytix Biopharma ASA for VP-315 (ruxotemitide) for non-melanoma skin cancers.

Argus 15 min delay

+0.66% vs previous close $5.33 last price 3.1x rel. volume Open Argus

Details

Market Reaction – VRCA

$5.04 $5.88 Day Range

$91.65M Market Cap

Following this news, VRCA has gained 0.66%, reflecting a mild positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $5.33. Trading volume is very high at 3.1x the average, suggesting strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Presentation date and time: September 14, 2026 at 1:00pm ET

Presentation date and time

September 14, 2026 at 1:00pm ET

H.C. Wainwright 28th Annual Global Investment Conference

Key Terms

molluscum contagiosum, non-melanoma skin cancers, FDA

3 terms

molluscum contagiosum medical

"treat adult and pediatric patients two years of age and older with molluscum contagiosum"

Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.

non-melanoma skin cancers medical

"develop and commercialize VP-315 for non-melanoma skin cancers"

Non-melanoma skin cancers are the common types of skin cancer that are not melanoma, most often basal cell carcinoma and squamous cell carcinoma; they typically arise from the outer skin layers after long-term sun exposure. For investors, they matter because high prevalence and usually ongoing treatment needs drive steady demand for drugs, surgical tools, diagnostics and dermatology services—think of them as frequent, predictable repairs to a building rather than rare major overhauls.

FDA regulatory

"approved by the FDA to treat adult and pediatric patients"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28^th Annual Global Investment Conference.

H.C. Wainwright 28^th Annual Global Investment Conference
Event details:
Date: Monday, September 14, 2026
Time: 1:00pm ET
Location: New York, NY

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

How can investors access Verrica Pharmaceuticals’ presentation at the H.C. Wainwright conference?

Participants may access a live webcast of Verrica’s presentation by clicking the provided webcast link. The webcast is also available in the Investors/Presentations & Events section of the company’s website at www.verrica.com.

Will a replay of Verrica’s conference presentation be available and for how long?

A replay of the webcast will be posted shortly after the presentation and will remain available for 90 days following the event.

What is YCANTH (VP-102) and for which patients is it approved?

YCANTH (VP-102) is a cantharidin-based treatment and is described as the first and only healthcare professional-administered therapy approved by the FDA for adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection that affects approximately 6 million people in the United States, primarily children.

For which additional indications is Verrica developing YCANTH (VP-102)?

YCANTH (VP-102) is also in development to treat common warts, which the company describes as the largest remaining unmet need in medical dermatology.

What is VP-315 and what agreement does Verrica have regarding this product?

VP-315 (ruxotemitide), formerly known as LTX-315 and VP-LTX-315, is being developed for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma. Verrica has a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize this product.